Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HPV vaccines under alternative 2-dose schedules in 9-14 year-old females, focusing on immunogenicity and safety; completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• GlaxoSmithKline HPV vaccine (GSK-580299) (HPV vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2016-03-28